Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001073590 | SCV001239141 | likely pathogenic | Retinal dystrophy | 2019-07-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003405293 | SCV004124076 | likely pathogenic | not provided | 2023-10-01 | criteria provided, single submitter | clinical testing | ABCA4: PM1, PM2, PM3, PM5 |
Labcorp Genetics |
RCV003405293 | SCV004292512 | pathogenic | not provided | 2024-04-25 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 1129 of the ABCA4 protein (p.Arg1129His). This variant is present in population databases (no rsID available, gnomAD 0.007%). This missense change has been observed in individual(s) with clinical features of ABCA4-related conditions (PMID: 23953153, 23982839, 32307445). ClinVar contains an entry for this variant (Variation ID: 865964). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg1129 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19074458, 25097241, 25312043, 26092729, 29925512). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005036386 | SCV005657388 | likely pathogenic | Cone-rod dystrophy 3; Age related macular degeneration 2; Severe early-childhood-onset retinal dystrophy; Retinitis pigmentosa 19 | 2024-05-16 | criteria provided, single submitter | clinical testing |